moxifloxacin has been researched along with Breast Cancer in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Trawneh, SA; Alfieri, RR; Cavazzoni, A; El-Abadelah, MM; Incerti, M; Kamal, MR; Petronini, PG; Vicini, P; Zahra, JA; Zani, F | 1 |
| Al-Taweel, SA; Al-Trawneh, SA; Cavazzoni, A; El-Abadelah, MM; Incerti, M; Vicini, P; Zahra, JA; Zani, F | 1 |
| Bi, X; Huang, J; Huang, Z; Li, J; Shi, W; Shi, Y; Su, Y; Wang, S; Wang, X; Xia, W; Yuan, Z | 1 |
| Astowo, P; Irawan, B; Magdalena, L; Maha, IHRT; Muthalib, A; Rinaldi, I; Susanto, N; Wicaksono, S | 1 |
| Asano, Y; Kashiwagi, S; Nagayama, K; Noda, S; Ogawa, K; Ohira, M; Onoda, N; Takahashi, K; Takahashi, M; Takashima, T | 1 |
| Adsule, S; Ahmad, A; Dandawate, P; Padhye, S; Patitungkho, S; Sarkar, FH | 1 |
1 trial(s) available for moxifloxacin and Breast Cancer
| Article | Year |
|---|---|
Efficacy of Moxifloxacin plus Treatment of Physician's Choice in Patients with Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Moxifloxacin; Physicians; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2020 |
5 other study(ies) available for moxifloxacin and Breast Cancer
| Article | Year |
|---|---|
Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line; Cell Line, Tumor; DNA Gyrase; DNA Topoisomerase IV; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Topoisomerase II Inhibitors | 2010 |
Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Thienopyridines; Topoisomerase II Inhibitors | 2011 |
The Role of Chest Radiograph, Procalcitonin and Moxifloxacin in Diagnosis and Management of Breast Cancer Patients with COVID-19.
Topics: Anti-Infective Agents; Antineoplastic Agents; Betacoronavirus; Breast Neoplasms; Clinical Laboratory Techniques; Comorbidity; Coronavirus Infections; COVID-19; COVID-19 Testing; Female; Humans; Mastectomy; Middle Aged; Moxifloxacin; Pandemics; Pneumonia, Viral; Procalcitonin; Radiography, Thoracic; SARS-CoV-2; Thyroid Neoplasms; Thyroidectomy; Treatment Outcome | 2020 |
Effectiveness and safety of the pre-prescription of garenoxacin in comparison to moxifloxacin for low-risk febrile neutropenia in breast cancer patients undergoing adjuvant and neoadjuvant chemotherapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoprevention; Chemotherapy-Induced Febrile Neutropenia; Chemotherapy, Adjuvant; Female; Fluoroquinolones; Follow-Up Studies; Humans; Middle Aged; Moxifloxacin; Neoadjuvant Therapy; Off-Label Use; Prior Authorization; Retrospective Studies; Risk Factors; Treatment Outcome | 2019 |
Synthesis, characterization and anti-tumor activity of moxifloxacin-copper complexes against breast cancer cell lines.
Topics: Apoptosis; Aza Compounds; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Copper; Drug Screening Assays, Antitumor; Female; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Spectrophotometry, Infrared | 2011 |